← Patent-cliff monitor small molecule BAXDELA DELAFLOXACIN MEGLUMINE
Loss of exclusivity June 2031 latest FDA-listed patent expiry
Company MELINTA SUBSIDIARY CORP
Drug detail Brand name BAXDELA Active ingredient DELAFLOXACIN MEGLUMINE Strength EQ 450MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2017 Marketing status RX
Listed patents Patent Expires Type 7728143 June 2031 substance RE46617 December 2029 substance 8871938 September 2029 substance 8252813 October 2026 product 8273892 August 2026 substance
Regulatory exclusivity Code Expires GAIN June 2027 NCE June 2022
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.